1[1]Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer.Br J Cancer, 2000, 82(9):1535
2[2]Rustin GJ, Nelstrop AE, Bentzen SM,et al. Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials. J Clin Oncol, 2000, 18(8):1733
3[3]Kato H.Radioimmunoassay of a tumor antigen of human squamous cell carcinoma. Cancer,1977, 40(3):1621
4[4]Suminami Y,Nagashima S,Vujanovic NL,et al.Inhibition of apoptosis in human tumor cell by the tumor-associated serpin, SCC antigen-1. Br J Cancer, 2000,82(4):981
5[9]Yuan CC, Wang PH, Ng HT, et al.Both TPA and SCC-Ag levels are prognostic even in high-risk stage Ib-IIa cervical carcinoma as determined by a stratification analysis. Eur J Gynaecol Oncol, 2002, 23(1): 17
6[11]Takeshima N,Hirai Y,Katase K,et al.The value of squamous cell carcinoma antigen as a predictor of nodal metastasis in cervical cancer. Gynecol Oncol, 1998,68(3):263
7[12]Takeda M, Sakuragi N, Okamoto K,et al. Preoperative serum SCC, CA125, and CA19-9 levels and lymph node status in squamous cell carcinoma of the uterine cervix. Acta Obstet Gynecol Scand, 2002, 81(5): 451
8[14]Scambia G,Benedetti P,Foti E,et al.Mutiple tumor marker assays in advanced cervical cancer:relationship to chemotherapy response and clinical outcome. Eur J Cancer,1996,32(2):259
9[15]Kim BG,Kim JH,Park SY,et al. Relationship between squamous cell carcinoma antigen levels and tumor volumes in patients with cervical carcinomas undergoing neoadjuvant chemotherapy. Gynecol Oncol,1996,63(1):105
10[16]Numa F. Squamous cell carcinoma antigen as a useful marker in neoadjuvant chemotherapy for locally advanced cancer of the uterine cervix. Tumor Biol, 2000 21(suppll):47
2Parkin DM, Bray F, Feday J, et al. Global cancer statistics, 2002 [J]. CA Cancer J Clin,2005,55(2) :74-108.
3Schiffman M, Castle PE, Jemnimo J, et al. Human papillomavirus and cervical cancer [J]. Lancet,2007,370(9590) :890-907.
4Molina R, Auge JM, Escudero JM, et al. Mucins CA 125, CA 19. 9, CA 15.3 and TAG-72. 3 as tumor markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE [ J]. Tumour Biol,2008,29(6) :371-380.
5Duffy MJ. Evidence for the clinical use of tumour markers [J]. Ann Clin Biochem,20Od- ,41 ( Pt 5 ) :370-377.
6Molina R,Filella X,Aug： JM,et al. CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA [ J ]. Anticancer Res,2005,25(3A) :1765-1771.
7Yuan CC,Wang PH,Ng HT, et al. Both TPA and SCC-Ag levels are prognostic even in high-risk stage Ib-IIa cervical carcinoma as determined by a stratification analysis [ J]. Eur J Gynaecol Oncol, 2002,23( 1 ) :17-20.
8Ohara K, Tanaka Y, Tsunoda H, et al. Assessment of cervical cancer radiorespanse by serum squamous cell carcinoma antigen and magnetic resonance imaging [J]. Obstet Gynecol,2002, 100 (4) :781-787.
9Micke O,Prott FJ, Schafer U, et al. The impact of squamous cell carcinoma (SCC) antigen in the fol：ow-np after radiotherapy in patients with cervical cancer [ J]. Anticancer Res,2000,20(6D) : 5113-5115.
